PDF(Pubmed)
Abstract：
UNASSIGNED: Recent studies suggested a relationship between Takotsubo syndrome (TTS) and malignancy. However, clinical outcomes of TTS associated with cancer have not been assessed completely. This study was aimed to investigate the outcomes of patients with TTS and cancer.
UNASSIGNED: We performed a systematic review and meta-analysis to evaluate the clinical outcomes of TTS in patients with and without malignancy. We systematically reviewed and analyzed 14 studies (189,210 patients) published in PubMed and Cochrane Library databases until December 2022. The primary outcome was all-cause mortality at the longest follow-up.
UNASSIGNED: The prevalence of current or previous malignancy in patients with TTS was 8.7% (16,461 patients). Patients with TTS and malignancy demonstrated a higher risk of mortality at the longest follow-up than those with TTS alone (odds ratio [OR], 2.41; 95% confidence interval [CI]; 1.95-2.98; P < 0.001). Moreover, cancer was significantly associated with an increased risk of in-hospital or 30-day mortality (OR 2.36; 95% CI, 1.67-3.33; P < 0.001), shock (OR 1.42; 95% CI, 1.30-1.55; P < 0.001), mechanical respiratory support (OR 1.68; 95% CI, 1.59-1.77; P < 0.001), arrhythmia (OR 1.27; 95% CI, 1.21-1.34; P < 0.001), and major adverse cardiac events (OR 1.69; 95% CI, 1.18-2.442; P < 0.001).
UNASSIGNED: This study revealed significant associations between previous or active cancer and an increased risk of all-cause mortality and in-hospital adverse events in patients with TTS.
UNASSIGNED: We performed a systematic review and meta-analysis to evaluate the clinical outcomes of TTS in patients with and without malignancy. We systematically reviewed and analyzed 14 studies (189,210 patients) published in PubMed and Cochrane Library databases until December 2022. The primary outcome was all-cause mortality at the longest follow-up.
UNASSIGNED: The prevalence of current or previous malignancy in patients with TTS was 8.7% (16,461 patients). Patients with TTS and malignancy demonstrated a higher risk of mortality at the longest follow-up than those with TTS alone (odds ratio [OR], 2.41; 95% confidence interval [CI]; 1.95-2.98; P < 0.001). Moreover, cancer was significantly associated with an increased risk of in-hospital or 30-day mortality (OR 2.36; 95% CI, 1.67-3.33; P < 0.001), shock (OR 1.42; 95% CI, 1.30-1.55; P < 0.001), mechanical respiratory support (OR 1.68; 95% CI, 1.59-1.77; P < 0.001), arrhythmia (OR 1.27; 95% CI, 1.21-1.34; P < 0.001), and major adverse cardiac events (OR 1.69; 95% CI, 1.18-2.442; P < 0.001).
UNASSIGNED: This study revealed significant associations between previous or active cancer and an increased risk of all-cause mortality and in-hospital adverse events in patients with TTS.
摘要：
■最近的研究表明Takotsubo综合征（TTS）与恶性肿瘤之间存在关系。然而,与癌症相关的TTS的临床结局尚未得到完全评估.本研究旨在探讨TTS和癌症患者的预后。
■我们进行了系统评价和荟萃分析，以评估有和没有恶性肿瘤的TTS患者的临床结局。我们系统回顾和分析了截至2022年12月发表在PubMed和CochraneLibrary数据库中的14项研究（189,210例患者）。主要结果是随访时间最长的全因死亡率。
■TTS患者当前或先前的恶性肿瘤患病率为8.7%（16,461例）。在最长的随访中，TTS和恶性肿瘤患者的死亡风险高于单独TTS患者（比值比[OR]，2.41；95%置信区间[CI]；1.95-2.98；P<0.001）。此外，癌症与住院或30天死亡风险增加显著相关(OR2.36;95%CI,1.67-3.33;P<0.001),休克（OR1.42；95%CI，1.30-1.55；P<0.001），机械呼吸支持(OR1.68;95%CI,1.59-1.77;P<0.001),心律失常(OR1.27;95%CI,1.21-1.34;P<0.001),和主要不良心脏事件（OR1.69；95％CI，1.18-2.442；P<0.001）。
这项研究揭示了TTS患者既往或活动性癌症与全因死亡率和院内不良事件风险增加之间的显著关联。
■我们进行了系统评价和荟萃分析，以评估有和没有恶性肿瘤的TTS患者的临床结局。我们系统回顾和分析了截至2022年12月发表在PubMed和CochraneLibrary数据库中的14项研究（189,210例患者）。主要结果是随访时间最长的全因死亡率。
■TTS患者当前或先前的恶性肿瘤患病率为8.7%（16,461例）。在最长的随访中，TTS和恶性肿瘤患者的死亡风险高于单独TTS患者（比值比[OR]，2.41；95%置信区间[CI]；1.95-2.98；P<0.001）。此外，癌症与住院或30天死亡风险增加显著相关(OR2.36;95%CI,1.67-3.33;P<0.001),休克（OR1.42；95%CI，1.30-1.55；P<0.001），机械呼吸支持(OR1.68;95%CI,1.59-1.77;P<0.001),心律失常(OR1.27;95%CI,1.21-1.34;P<0.001),和主要不良心脏事件（OR1.69；95％CI，1.18-2.442；P<0.001）。
这项研究揭示了TTS患者既往或活动性癌症与全因死亡率和院内不良事件风险增加之间的显著关联。
